Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study

被引:29
|
作者
Pumthong, Ganniga [1 ]
Asawanonda, Pravit [2 ]
Varothai, Supenya [3 ]
Jariyasethavong, Vorapicha [2 ]
Triwongwaranat, Daranporn [3 ]
Suthipinittharm, Puan [4 ]
Ingkaninan, Kornkanok [5 ]
Leelapornpisit, Pimporn [6 ]
Waranuch, Neti [1 ]
机构
[1] Naresuan Univ, Fac Pharmaceut Sci, Cosmet & Nat Prod Res Ctr, Phitsanulok 65000, Thailand
[2] Chulalongkorn Univ, Fac Med, Dept Med, Div Dermatol, Bangkok 10330, Thailand
[3] Mahidol Univ, Fac Med, Siriraj Hosp, Dept Dermatol, Bangkok 10700, Thailand
[4] Ubon Ratchathani Univ, Coll Med & Publ Hlth, Warin Chamrap, Thailand
[5] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharmaceut Chem & Pharmacognosy, Phitsanulok, Thailand
[6] Chiang Mai Univ, Fac Pharmaceut Sci, Chiang Mai 50000, Thailand
关键词
alopecia; Curcuma aeruginosa; minoxidil; pattern baldness; 5 alpha-reductase inhibitor; 2-PERCENT TOPICAL MINOXIDIL; ANDROGENETIC ALOPECIA; HAIR LOSS; CONTROLLED TRIAL; CLINICAL-TRIAL; 5-PERCENT; MEN;
D O I
10.3109/09546634.2011.568470
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Several botanically derived agents are available for the treatment of male-pattern baldness. Objective: The aim of this study was to evaluate the efficacy of 5% hexane extract of Curcuma aeruginosa, a botanically derived inhibitor of 5 alpha-reductase and 5% minoxidil in the treatment of androgenetic alopecia. Methods: Eighty-seven men with androgenetic alopecia (AGA) were randomized to receive 5% Curcuma aeruginosa, 5% minoxidil, combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil) or placebo, twice daily for 6 months. Efficacy was assessed by target area hair count, global photographic review as well as patients' subjective assessments of hair regrowth and hair shedding. Results: There were statistically significant improvements in global photographic review (p < 0.001), subjects' overall assessments of hair regrowth (p = 0.008), and hair shedding (p = 0.004) when the combination formulation was compared with placebo. Similarly, treatment with 5% minoxidil and 5% C. aeruginosa extract also led to some degrees of hair regrowth. There were no serious adverse events during and after the study. Conclusion: In men with hair loss in the vertex area of the scalp, the combination of 5% hexane extract of C. aeruginosa and 5% minoxidil slowed hair loss and increased hair growth.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 50 条
  • [1] Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study
    Blume-Peytavi, Ulrike
    Issiakhem, Zahida
    Gautier, Stephanie
    Kottner, Jan
    Wigger-Alberti, Walter
    Fischer, Tobias
    Hoffmann, Rolf
    Tonner, Francoise
    Bouroubi, Athmane
    Voisard, Jean-Jacques
    JOURNAL OF COSMETIC DERMATOLOGY, 2019, 18 (01) : 215 - 220
  • [2] Targeted nalmefene with simple medical management in the treatment of heavy drinkers:: A randomized double-blind placebo-controlled multicenter study
    Karhuvaara, Sakari
    Simojoki, Kaarlo
    Virta, Antti
    Rosberg, Markus
    Loyttyniemi, Eliisa
    Nurminen, Tommi
    Kallio, Antero
    Makela, Rauno
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (07) : 1179 - 1187
  • [3] Evaluation of the Efficacy and Safety of Topical Procyanidin B2 and Placebo in the Treatment of Androgenetic Alopecia in Men; A Randomized, Double-blind, Placebo-controlled Study
    Yeniay, Yildiray
    Arca, Ercan
    TURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGY, 2022, 16 (04): : 108 - 114
  • [4] Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
    Kim, Sue Youn
    Yun, Jae Moon
    Lee, Ji-Won
    Cho, Young Gyu
    Cho, Kyung-Hwan
    Park, Yong Gyu
    Cho, Belong
    CLINICAL THERAPEUTICS, 2021, 43 (10) : 1757 - +
  • [5] Oxcarbazepine -: Efficacy and tolerability during treatment of alcohol withdrawal:: A double-blind, randomized, placebo-controlled multicenter pilot study
    Koethe, Dagmar
    Juelicher, Antje
    Nolden, Brit M.
    Braunwarth, Wolf-Dietrich
    Klosterkoetter, Joachim
    Niklewski, Guenter
    Wodarz, Norbert
    Klatt, Jan
    Burtscheidt, Wilhelm
    Gaebel, Wolfgang
    Leweke, F. Markus
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (07) : 1188 - 1194
  • [6] SIAXI Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
    Jost, Wolfgang H.
    Friedman, Andrzej
    Michel, Olaf
    Oehlwein, Christian
    Slawek, Jaroslaw
    Bogucki, Andrzej
    Ochudlo, Stanislaw
    Banach, Marta
    Pagan, Fernando
    Flatau-Baque, Birgit
    Csikos, Janos
    Cairney, Claire J.
    Blitzer, Andrew
    NEUROLOGY, 2019, 92 (17) : E1982 - E1991
  • [7] Transdermal buprenorphine in the treatment of chronic pain: Results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study
    Sorge, J
    Sittl, R
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1808 - 1820
  • [8] Augmenting Clozapine With Sertindole A Double-Blind, Randomized, Placebo-Controlled Study
    Nielsen, Jimmi
    Emborg, Charlotte
    Gydesen, Susanne
    Dybbro, Jesper
    Aagaard, Jorgen
    Haderup, Karsten
    Glyngdal, Pia
    Fabricius, Susanne
    Thode, Dorrit
    Lublin, Henrik
    Andersen, Torben
    Damkier, Per
    Taylor, David
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (02) : 173 - 178
  • [9] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Loki zupa in Patients With Chronic Asthma
    Lv, Yubao
    Wei, Ying
    Abduwaki, Muhammadjan
    Jurat, Tohti
    Li, Fengsen
    Wang, Huaizhen
    Wu, Yuhua
    Li, Zheng
    Liu, Bo
    Yin, Hongjun
    Cao, Yuxue
    Nurahmat, Mammat
    Tang, Zihui
    Dong, Jingcheng
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [10] A double-blind randomized, multicenter, placebo-controlled study of itopride in functional dyspepsia postprandial distress syndrome
    Carbone, Florencia
    Vandenberghe, Alain
    Holvoet, Lieselot
    Piessevaux, Hubert
    Arts, Joris
    Caenepeel, Philippe
    Staessen, Dirk
    Vergauwe, Philippe
    Maldague, Philippe
    De Ronde, Thierry
    Wuestenberghs, Fabien
    Lamy, Vincent
    Lefebvre, Veronique
    Latour, Pascale
    Vanuytsel, Tim
    Jones, Michael
    Tack, Jan
    NEUROGASTROENTEROLOGY AND MOTILITY, 2022, 34 (08)